271. Ankylosing spondylitis Clinical trials / Disease details
Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02762812 (ClinicalTrials.gov) | January 2016 | 4/4/2016 | Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis | International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade® in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | Biological: BCD-055;Biological: Remicade® | Biocad | NULL | Completed | 18 Years | 65 Years | All | 199 | Phase 3 | Russian Federation |
| 2 | NCT02359903 (ClinicalTrials.gov) | February 2015 | 30/1/2015 | Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis | International Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: Infliximab (BCD-055);Drug: Infliximab (Remicade) | Biocad | NULL | Completed | 18 Years | 65 Years | All | 90 | Phase 1 | Belarus;Russian Federation |